NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
Associated ConditionsCancer, Multiple Tumor Types
Children's Oncology Group
You are being asked to take part in this research study because your tumor results from the NCI-COG Pediatric MATCH screening protocol make you a candidate to receive the study drug called BVD-523FB (ulixertinib) that we are testing in this study. The overall goal of this study is to test any good and bad effects of the study drug BVD-523FB (ulixertinib) on your tumor. A second goal of the study is to evaluate side effects that might be caused by BVD-523FB (ulixertinib), which could shrink your cancer but it could also cause side effects and to learn more about the pharmacology (how your body handles the drug) of BVD-523FB (ulixertinib).
This study is currently enrolling.